News Akebia joins GSK in US market for oral CKD anaemia drugs The FDA has approved Akebia Therapeutics’ vadadustat as a treatment for anaemia caused by chronic kidney disease (CKD) in dialysis patients, becoming the first rival to GS
News FDA approves GSK’s oral treatment of dialysis anaemia The US Food and Drug Administration (FDA) has approved the
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face